Literature DB >> 33384684

What Makes Antibodies Against G Protein-Coupled Receptors so Special? A Novel Concept to Understand Chronic Diseases.

Gabriela Riemekasten1,2,3,4, Frank Petersen2,3,4, Harald Heidecke5.   

Abstract

Expressions of G protein-coupled receptors (GPCR) on immune and tissue resident cells are the consequence of the cellular environment, which is highly variable. As discussed here, antibodies directed to GPCR (GPCR abs), their levels and correlations to other abs, serve as biomarkers for various diseases. They also could reflect the individual interplay between the environment and the immune system. Thus, GPCR abs could display pathogenic chronic conditions and could help to identify disease-related pathways. Moreover, by acting as ligands to their corresponding receptors, GPCR abs modulate autoimmune as well as non-autoimmune diseases. This article introduces GPCR abs as drivers for diseases by their capability to induce a specific signaling and by determining immune cell homeostasis. The identification of the individual GPCR ab function is challenging but might be pivotal in the comprehension of the aetiology of diseases. This, hopefully, will lead to the identification of novel therapeutic strategies. This article provides an overview about concepts and recent developments in research. Accordingly, GPCR abs could represent ideal candidates for precision medicine. Here, we introduce the term antibodiom to cover the network of abs with GPCR abs as prominent players.
Copyright © 2020 Riemekasten, Petersen and Heidecke.

Entities:  

Keywords:  G protein-coupled receptors; angiotensin receptor 1; anti-G protein-coupled receptor antibodies; immune cell homeostasis; precision medicine

Mesh:

Substances:

Year:  2020        PMID: 33384684      PMCID: PMC7770155          DOI: 10.3389/fimmu.2020.564526

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  53 in total

1.  Decreased endothelin receptor A autoantibody levels are associated with early ischaemic events in patients with giant-cell arteritis.

Authors:  Sebastian Klapa; Antje Müller; Andreas Koch; Harald Heidecke; Wataru Kähler; Juliane Junker; Susanne Schinke; Gabriela Riemekasten; Peter Lamprecht
Journal:  Ann Rheum Dis       Date:  2019-06-11       Impact factor: 19.103

2.  The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.

Authors:  Katrin Kreienbring; Annika Franz; Rolf Richter; Duska Dragun; Harald Heidecke; Dominik Müller; Monika Mentze; Ralf Dechend; Jalid Sehouli; Elena Ioana Braicu
Journal:  Anticancer Res       Date:  2018-06       Impact factor: 2.480

3.  TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY.

Authors:  George J Kahaly; Tanja Diana; Paul D Olivo
Journal:  Endocr Pract       Date:  2020-01       Impact factor: 3.443

4.  Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis.

Authors:  Jingwei Lv; Ling Li; Wei Li; Kunqian Ji; Ying Hou; Chuanzhu Yan; Tingjun Dai
Journal:  J Neuroimmunol       Date:  2018-01-09       Impact factor: 3.478

Review 5.  Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases.

Authors:  Otavio Cabral-Marques; Gabriela Riemekasten
Journal:  Nat Rev Rheumatol       Date:  2017-08-31       Impact factor: 20.543

6.  Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease.

Authors:  D J Abraham; R Vancheeswaran; M R Dashwood; V S Rajkumar; P Pantelides; S W Xu; R M du Bois; C M Black
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

7.  Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

Authors:  Duska Dragun; Dominik N Müller; Jan Hinrich Bräsen; Lutz Fritsche; Melina Nieminen-Kelhä; Ralf Dechend; Ulrich Kintscher; Birgit Rudolph; Johan Hoebeke; Diana Eckert; Istvan Mazak; Ralph Plehm; Constanze Schönemann; Thomas Unger; Klemens Budde; Hans-Hellmut Neumayer; Friedrich C Luft; Gerd Wallukat
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

8.  Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody.

Authors:  Jane Sanders; Dimitri Y Chirgadze; Paul Sanders; Stuart Baker; Andrew Sullivan; Anshu Bhardwaja; Jane Bolton; Magnus Reeve; Nobuhiro Nakatake; Michele Evans; Tonya Richards; Michael Powell; Ricardo Núñez Miguel; Tom L Blundell; Jadwiga Furmaniak; Bernard Rees Smith
Journal:  Thyroid       Date:  2007-05       Impact factor: 6.568

9.  Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen.

Authors:  F C Moazedi-Fuerst; S M Kielhauser; K Brickmann; J Hermann; A Lutfi; M Meilinger; H P Brezinschek; W B Graninger
Journal:  Scand J Rheumatol       Date:  2014-03-11       Impact factor: 3.641

10.  Angiotensin II type 1 and 2 receptors and lymphatic vessels modulate lung remodeling and fibrosis in systemic sclerosis and idiopathic pulmonary fibrosis.

Authors:  Edwin Roger Parra; Aline Domingos Pinto Ruppert; Vera Luiza Capelozzi
Journal:  Clinics (Sao Paulo)       Date:  2014-01       Impact factor: 2.365

View more
  7 in total

Review 1.  Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases.

Authors:  Orkid Coskuner-Weber; Ozan Mirzanli; Vladimir N Uversky
Journal:  Biophys Rev       Date:  2022-06-08

2.  Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease.

Authors:  Carmen M Labandeira; Maria A Pedrosa; Aloia Quijano; Rita Valenzuela; Pablo Garrido-Gil; Mariña Sanchez-Andrade; Juan A Suarez-Quintanilla; Ana I Rodriguez-Perez; Jose L Labandeira-Garcia
Journal:  NPJ Parkinsons Dis       Date:  2022-06-14

3.  Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching.

Authors:  Xiaoyang Yue; Junping Yin; Xiaoqing Wang; Harald Heidecke; Alexander Maximilian Hackel; Xiaoru Dong; Brigitte Kasper; Lifang Wen; Liang Zhang; Kai Schulze-Forster; Juliane Junker; Hanna Grasshoff; Antje Müller; Gerd Wallukat; Ingolf Schimke; Julian Zeiner; Lisa Marie Deckstein; Nicole Mertens; Anja Kerstein-Staehle; Jennifer Elisabeth Hundt; Evi Kostenis; Xinhua Yu; Gabriela Riemekasten; Frank Petersen
Journal:  Ann Rheum Dis       Date:  2022-05-20       Impact factor: 27.973

Review 4.  A broad look into the future of systemic sclerosis.

Authors:  Gabriela Riemekasten; Jörg H W Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-08-09       Impact factor: 3.625

Review 5.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

6.  Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity.

Authors:  Franziska Sotzny; Igor Salerno Filgueiras; Claudia Kedor; Helma Freitag; Kirsten Wittke; Sandra Bauer; Nuno Sepúlveda; Dennyson Leandro Mathias da Fonseca; Gabriela Crispim Baiocchi; Alexandre H C Marques; Myungjin Kim; Tanja Lange; Desirée Rodrigues Plaça; Finn Luebber; Frieder M Paulus; Roberta De Vito; Igor Jurisica; Kai Schulze-Forster; Friedemann Paul; Judith Bellmann-Strobl; Rebekka Rust; Uta Hoppmann; Yehuda Shoenfeld; Gabriela Riemekasten; Harald Heidecke; Otavio Cabral-Marques; Carmen Scheibenbogen
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

7.  Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA.

Authors:  Lukas Bankamp; Beate Preuß; Ann-Christin Pecher; Nicola Beucke; Jörg Henes; Reinhild Klein
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.